Abstracts tagged "Disease Activity"

Abstract Number: 0861 • ACR Convergence 2021
Systemic Lupus Erythematosus, a Pilot Study of a New Disease Activity Score
Daphna Paran¹, Monique Ben-Am², Liran Mendel², Ari Polachek³, Victoria Furer², Ofir Elalouf⁴, Jonathan Wollman⁴, Shaye Kivity⁵ and Nancy Agmon-Levin⁶, ¹Tel Aviv Sourasky Medical Center-Ichilov Hospital, Even Yehuda, Israel, ²Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ³Sourasky Medical Center, Petah-Tikva, Israel, ⁴Tel Aviv Medical Center, Herzliya, Israel, ⁵Meir Medical Center, Kefar Saba, Israel, ⁶Sheba Medical Center, Ramat Gan, Israel
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous, waxing and waning, multisystem autoimmune disease. The complexity and clinical unpredictability of SLE challenge the assessment of…
Abstract Number: 1204 • ACR Convergence 2021
CXCL13 Outranges DAS28CRP and CRP as Predictor of Long-term Radiographic Status in Early Rheumatoid Arthritis
Stinne Greisen¹, Merete Hetland², Mikkel Ostergaard³, Kim Horslev-Petersen⁴, Peter Junker⁵, Kristian Stengaard-Petersen⁶, Malene Hvid¹ and Bent Deleuran¹, ¹Aarhus University, Aarhus, Denmark, ²DANBIO and COPECARE, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, ³Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, and Department of Clinical Medicine, University of Copenhagen, Glostrup, Denmark, ⁴King Christian 10th Hospital for the Rheumatic Diseases, and University of Southern Denmark, Aabenraa, Denmark, ⁵Department of Rheumatology, Odense University Hospital, Odense C, Denmark, ⁶Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: In a cohort of early rheumatoid arthritis (eRA) patients, we recently showed that early and aggressive treatment led to remission and limited erosive progression…
Abstract Number: 1293 • ACR Convergence 2021
Studying Clusters of Patients with SLE According to Cognitive Function, Self-reported Outcomes, Disease Activity, and Clusters Dynamic over 1 Year
Ambika Gupta¹, Sindhu Johnson², Jiandong Su³, Kathleen Bingham⁴, Andrea Knight⁵, Juan Diaz-Martinez⁶, Mahta Kakvan³, Maria Tartaglia³, Lesley Ruttan⁴, Joan Wither³, May Choi⁷, Marvin Fritzler⁸, Dennisse Bonilla³, Dorcas Beaton⁹, Patricia Katz¹⁰, Robin Green³ and Zahi Touma¹, ¹University of Toronto, Mississauga, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³University Health Network, Toronto, ON, Canada, ⁴University of Toronto, University Health Network, Toronto, ON, Canada, ⁵Hospital for Sick Children, Toronto, ON, Canada, ⁶UHN, Toronto, ON, Canada, ⁷Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, ⁸University of Calgary, Calgary, AB, Canada, ⁹Institute for Work & Health, Toronto, ON, Canada, ¹⁰University of California San Francisco, San Francisco, CA
Background/Purpose: Systemic Lupus Erythematosus (SLE) has a high prevalence of cognitive impairment (CI) (38% (95% confidence interval: 33-43%)). Patient reported outcomes (PROs) capture patient perceptions…
Abstract Number: 1638 • ACR Convergence 2021
Clinical Manifestations of COVID-19 and Its Impact on Pediatric Patients with Rheumatic Disease
Belina Yi, Sindhu Mohandas and Michal Cidon, Children's Hospital Los Angeles, Los Angeles, CA
Background/Purpose: Spread of SARS-COV-2 during the COVID-19 pandemic has raised concerns for patients with rheumatic disease. Rheumatology patients have an increased risk of developing infectious…
Abstract Number: 1874 • ACR Convergence 2021
Using 18F-fluorodeoxyglucose Positron Emission Tomography to Standardize Clinical Trial Recruitment in Takayasu’s Arteritis
Kaitlin Quinn¹, Hugh Alessi², Emily Rose³, Mark A. Ahlman⁴, Christopher Redmond⁴, Yiming Luo⁴, Ertugrul Cagri bolek⁵, Carol Langford⁶, Cristina Ponte⁷, Peter Merkel⁸ and Peter Grayson⁹, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Washington, DC, ²National Institutes of Health, Bethesda, Maryland, ³Case Western, Cleveland Heights, OH, ⁴National Institutes of Health, Bethesda, MD, ⁵Vasculitis Translational Research Program, NIAMS, NIH, US, Lanham, MD, ⁶Cleveland Clinic, Moreland Hills, OH, ⁷Hospital de Santa Maria, Lisbon, Portugal, ⁸University of Pennsylvania, Philadelphia, PA, ⁹National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD
Background/Purpose: Disease activity assessment can be challenging in Takayasu’s arteritis (TAK), which can lead to difficulty in determining eligibility for enrollment into randomized clinical trials…
Abstract Number: 0032 • ACR Convergence 2021
IL-40: A New B-cell Associated Cytokine Up-regulated in Rheumatoid Arthritis Decreases Following the Rituximab Therapy and Correlates with Disease Activity, Autoantibodies and NETosis
Adela Navratilova¹, Lucie Andrés Cerezo¹, Hana Hulejová², Viktor Bečvář², Michal Tomcik³, Dana Tegzova², Martina Olejárová¹, David Veigl⁴, Karel Pavelka³, Jiri Vencovsky² and Ladislav Senolt³, ¹Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ²Institute of Rheumatology, Prague, Czech Republic, ³Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ⁴First Orthopaedic Clinic, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: Interleukin 40 (IL-40) is recently identified B cell - associated cytokine implicated in humoral immune responses and in B cell development and homeostasis. As…
Abstract Number: 0340 • ACR Convergence 2021
Urinary L-selectin Predicts Disease Activity and Histological Changes in Lupus Nephritis
Huihua Ding¹, Yiwei Shen¹, Min Dai¹, Chandra Mohan² and Nan Shen³, ¹Shanghai JiaoTong University School of Medicine, Shanghai, China (People's Republic), ²University of Houston, Houston, TX, ³Shanghai Jiang Tong University School of Medicine, Shanghai, China (People's Republic)
Background/Purpose: There remains unmet needs of non-invasive markers of disease activity, damage, prognosis, and treatment response in lupus nephritis patients. Here, we aim to validate…
Abstract Number: 0722 • ACR Convergence 2021
Myostatin in Idiopathic Inflammatory Myopathies: Seric Assessment and Disease Activity
Alexandrine Mahoudeau¹, Céline Anquetil², Nozomu Tawara¹, Hossein Khademian¹, Damien Amelin¹, Yves Allenbach³ and Olivier Benveniste³, ¹Center of Research in Myology, Sorbonne University, Paris, France, ²Center of Research in Myology, Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Clinical Immunology and Internal Medicine, Paris, France, ³Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Clinical Immunology and Internal Medicine, Paris, France
Background/Purpose: In Idiopathic Inflammatory Myopathies (IIM) disease activity is very difficult to assess and IIM may induce severe muscle damage, especially in immune-mediated necrotizing myopathies…
Abstract Number: 0873 • ACR Convergence 2021
Clinical and Serological Characteristics of Latin American Patients with Lupus Enteritis: A Case-Control Study
Marcela Muñoz-Urbano¹, Julian Sanchez-Bautista², Yeison Santamaria-Alza¹, Diana C. Quintero-González³, Andres Ramirez², Adriana Lucía Vanegas-García⁴, Gloria M. Vasquez¹ and Luis Alonso Gonzalez³, ¹Rheumatology section, Universidad de Antioquia, Medellín, Colombia, ²Department of internal medicine, Universidad de Antioquia, Medellín, Colombia, ³Division of rheumatology, Universidad de Antioquia, Medellín, Colombia, ⁴Division of rheumatology, Universidad de Antioquia – Hospital San Vicente Fundación, Medellín, Colombia
Background/Purpose: Lupus enteritis (LE) is a potentially life-threatening manifestation of systemic lupus erythematosus (SLE), with an incidence ranging from 8% to 27%. Timely diagnosis is…
Abstract Number: 1212 • ACR Convergence 2021
Prediction of 1-Year Intravenous Abatacept Retention in Patients with RA Using Novel Machine Learning Techniques: Directionality and Importance of Predictors
Rieke Alten¹, Claire Behar², Christine Boileau³, Pierre Merckaert⁴, Ebenezer Afari⁵, Virginie Vannier-Moreau⁶, Anael Ohayon⁶, Sean Connolly⁷, Aurelie Najm⁸, Pierre Antoine Juge⁹, Gengyuan Liu⁷, Angshu Rai¹⁰, Yedid Elbez¹¹ and Karissa Lozenski⁷, ¹Schlosspark-Klinik University, Berlin, Germany, ²Tulsy, Paris, France, ³Excelya, Boulogne-Billancourt, France, ⁴Data Revenue GmbH, Berlin, Germany, ⁵Private Practice, Brunoy, France, ⁶Bristol Myers Squibb, Rueil-Malmaison, France, ⁷Bristol Myers Squibb, Princeton, NJ, ⁸Institute of Infection, Immunity and Inflammation, College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ⁹Hopital Bichat-Claude Bernard, Service de Rhumatologie, Paris, France, ¹⁰Bristol Myers Squibb (at the time of analysis), Princeton, NJ, ¹¹Deepscover, Puteaux, France
Background/Purpose: In the ACTION study (NCT02109666), previous multivariable Cox proportional-hazards regression models showed that predictors of 1-year retention to intravenous abatacept treatment included: patient global…
Abstract Number: 1295 • ACR Convergence 2021
Belimumab Reduces Severe Flares in Systemic Lupus Erythematosus Across Multiple Patient Subgroups: Results of a Large Integrated Analysis
Michelle Petri¹, Norma Lynn Fox², Mathew Gibb³, Tania Gonzalez-Rivera², Anne Hammer², Holly Quasny⁴, Ronald van Vollenhoven⁵ and David Roth², ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²GlaxoSmithKline, Collegeville, PA, ³Veramed Ltd., Twickenham, United Kingdom, ⁴GlaxoSmithKline, Research Triangle Park, NC, ⁵Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Center, Amsterdam Rheumatology Center, Amsterdam, Netherlands
Background/Purpose: Belimumab (BEL) is a disease-modifying systemic lupus erythematosus (SLE) treatment that inhibits B-lymphocyte stimulator. BEL has demonstrated a consistent efficacy profile across 4 pivotal…
Abstract Number: 1653 • ACR Convergence 2021
Positron Emission Tomography-Detected Uptake of 18F-Fluorodeoxyglucose in Visceral and Subcutaneous Adipose Tissue Is Associated with Articular Disease Activity and Arterial Inflammation in Rheumatoid Arthritis
Jon Giles¹, Joan Bathon², Hadil Zureigat³ and Ahmed Tawakol⁴, ¹Columbia University Irving Medical Center, Division of Rheumatology, New York, NY, ²Columbia University, New York, NY, ³Harvard University, Boston, MA, ⁴Harvard University/Massachusetts General Hospital, Boston, MA
Background/Purpose: Subcutaneous adipose tissue (SAT) from people with RA contains more macrophages and expresses higher levels of cytokines, chemokines, and other inflammatory mediators compared with…
Abstract Number: 1879 • ACR Convergence 2021
Delayed Diagnosis of IgG4 Related Disease Is Associated with Worse Outcome: A Retrospective, Real-life Observational Study
Elisheva Pokroy-Shapira¹, Iftach Sagy², Katya Meridor³ and Yair Molad⁴, ¹Institute of Rheumatology, Rabin Medical Center, Beilinson Hospital, and Tel Aviv University, Petach Tikva, Israel, ²Clinical Research Center, Soroka University Medical Center, Beer Sheva and Ben Gurion University of the Negev, DVIRA, Israel, ³Tel Aviv Sourasky Medical Center, Kfar Saba, Israel, ⁴Rabin Medical Center, Beilinson Hospital, and Tel Aviv University, Petah-Tikva, Israel
Background/Purpose: The purpose of this study was to characterize clinical and pathological features as well as disease outcome of an Israeli incident cohort of patients…
Abstract Number: 0033 • ACR Convergence 2021
Impaired Adipose Tissue Function in Rheumatoid Arthritis: Association with Autoimmunity, Disease Activity and Therapeutic Response
Iván Arias de la Rosa¹, alejandro Escudero², Cristobal Román-Rodriguez², Rocio Guzmán-Ruiz², Maria del Mar Malagón², Carlos Pérez-Sánchez³, Chamaida Plasencia-Rodríguez⁴, Ana Martinez-Feito⁵, Maria del Carmen Ábalos-Aguilera², Alejandra Patiño-Trives⁶, Jerusalem Calvo², Rafaela Ortega², Eduardo Collantes-Estevez², Chary Lopez-Pedrera² and Nuria Barbarroja¹, ¹University of Cordoba/IMIBIC/Reina Sofia Hospital, Cordoba, Spain, ²IMIBIC/Reina Sofia Hospital/University of Córdoba, Córdoba, Spain, ³IMIBIC, Córdoba, Spain, ⁴Immuno-Rheumatology Research Group, Hospital La Paz Institute for Health Research-IdiPAZ, Rheumatology, La Paz University Hospital, Madrid, Spain, ⁵ImmunoRheumatology Department, IDIPAZ, Madrid, Spain, ⁶Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain
Background/Purpose: 1) to evaluate the relationship among adipose tissue dysfunction, autoimmunity and disease activity in rheumatoid arthritis (RA) patients; 2) to analyze the direct effect…
Abstract Number: 0344 • ACR Convergence 2021
Anti-gAChR Antibody as a Novel Biomarker for Lupus Enteritis in Systemic Lupus Erythematosus
Kuniyuki Aso¹, Michihito Kono¹, Keita Ninagawa¹, Nobuya Abe¹, Yuichiro Fujieda¹, Masaru Kato¹, Olga Amengual¹, Kenji Oku¹ and Tatsuya Atsumi², ¹Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, ²Hokkaido University, Sapporo, Japan
Background/Purpose: Anti-ganglionic nicotinic acetylcholine receptor (gAChR) antibody (Ab) is associated with widespread autonomic dysfunction in autoimmune autonomic ganglionopathy. Although it is also detected in several…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].